載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.4671
−US$0.002 · -0.43%
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
前收盤價
US$0.4671
−US$0.002 · -0.43%
盤中時間採用ET。市場資料可能有所延遲。
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
日內區間
目前US$0.4671
52週區間
目前US$0.4671
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
50
合理估值
情緒
56
多空交錯
風險
70
高風險
動能
35
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
日內區間
目前US$0.4671
52週區間
目前US$0.4671
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 106.02萬 USD | 213萬 USD | 690.8萬 USD | 157.93萬 USD | 8.2萬 USD |
| 銷售、一般及管理費用 | 217.48萬 USD | 208.9萬 USD | 252萬 USD | 208.59萬 USD | 102.1萬 USD |
| 營業費用 | 323.49萬 USD | 421.9萬 USD | 942.8萬 USD | 366.52萬 USD | 110.31萬 USD |
| 利息收入 | 12.2萬 USD | 5.57萬 USD | 1868 USD | — | 805.11 USD |
| 利息支出 | — | — | — | 73.17萬 USD | 80.51萬 USD |
| 折舊和攤銷 | — | 421.92萬 USD | 942.83萬 USD | — | — |
| 營業利益 | −323.49萬 USD | −421.9萬 USD | −942.8萬 USD | −366.52萬 USD | −110.31萬 USD |
| 淨利 | −310.9萬 USD | −411.2萬 USD | −894.9萬 USD | −148.46萬 USD | −161.07萬 USD |
公司資料更新於 2026年10月11日。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
